KORU Medical Systems, Inc. (KRMD)

NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-10-23

$3.17+2.92%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge KORU Medical Systems, Inc.’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
FY 2026 · Q4
Revenue	—	12.93M
EPS	—	-0.007
FY 2026 · Annual
Revenue	$47.5M–$48.5M	48.04M
EPS	—	-0.039
Gross margin	62%–64%	—
FY 2027 · Annual
Revenue	—	56.3M
EPS	—	0.021

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Maintain gross margin between 61-63% in 2026	Gross margin is steady near 62%.	Intact	gross margin falls below 61% in FY26	Gross margin: 65.14% FY2026-Q2; GAAP. Published target: 61-63%. Target period is not explicitly aligned with this observation. Source published Aug 5, 202665.138517 percent · calculatedSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 746ca80b-28d9-4c9e-9551-dc8ad9493f6c. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 3 of last 3 quarters. Gross margin improved from 61.5% in 2026-Q1 to 65.1% in 2026-Q2, exceeding the guided range of 61% to 64%. Management has consistently reiterated this gross margin target and the trajectory shows delivering and slight improvement beyond guidance. Delivery assessment Oct 24, 2026
Achieve positive adjusted EBITDA and cash flow in 2026	Management targets positive adjusted EBITDA and cash flow this year.	Improving	adjusted EBITDA and cash flow remain negative through FY26	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 3 of last 3 quarters. Adjusted EBITDA improved from $0.3 million in 2025-Q2 to $0.9 million in 2026-Q2, with positive cash flow from operations reported in 2026-Q1 and Q2. Management has consistently reiterated this goal and the trajectory is delivering positive adjusted EBITDA and improving cash flow. Delivery assessment Oct 24, 2026
Achieve 15-22% revenue growth in 2026	A primary condition in KORU Medical Systems, Inc.'s published investment case. The stated target is 15-22% YoY growth.	Intact	YoY revenue growth falls below 15% in FY26	Revenue growth: 18.15% FY2026-Q2; GAAP. Published target: 15-22% YoY growth. Target period is not explicitly aligned with this observation. Source published Aug 5, 202618.152588 percent · calculatedSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 746ca80b-28d9-4c9e-9551-dc8ad9493f6c. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 3 of last 3 quarters. Revenue increased 18.2% year-over-year to $12.0 million in 2026-Q2 from $10.2 million in 2025-Q2, aligning with management's guidance of 15% to 22% growth for 2026. The trajectory is delivering consistent revenue growth as committed. Delivery assessment Oct 24, 2026

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS: comparable history unavailable.

FY2027 revenueUnavailable

Unavailable → Unavailable · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	Unavailable	Unavailable	3 / 4
2026-07-25	Unavailable	$56,935,400	2 / 5
2026-07-26	Unavailable	$56,935,400	2 / 5
2026-07-27	Unavailable	Unavailable	3 / 4
2026-07-28	Unavailable	Unavailable	3 / 4
2026-07-29	Unavailable	$56,935,400	2 / 5
2026-07-30	Unavailable	$56,935,400	2 / 5
2026-07-31	Unavailable	$56,935,400	2 / 5
2026-08-01	Unavailable	Unavailable	3 / 4
2026-08-02	Unavailable	$56,935,400	2 / 5
2026-08-03	Unavailable	$56,935,400	2 / 5
2026-08-04	Unavailable	$56,935,400	2 / 5
2026-08-05	Unavailable	$56,935,400	2 / 5
2026-08-06	Unavailable	Unavailable	3 / 4
2026-08-07	Unavailable	Unavailable	3 / 4
2026-08-08	Unavailable	$56,183,200	2 / 5
2026-08-09	Unavailable	Unavailable	3 / 4
2026-08-10	Unavailable	$56,183,200	2 / 5
2026-08-12	Unavailable	$56,183,200	2 / 5
2026-08-13	Unavailable	$56,183,200	2 / 5
2026-08-14	Unavailable	Unavailable	3 / 4
2026-08-15	Unavailable	Unavailable	3 / 4
2026-08-16	Unavailable	Unavailable	3 / 4
2026-08-17	Unavailable	Unavailable	3 / 4
2026-08-18	Unavailable	Unavailable	3 / 4
2026-08-19	Unavailable	Unavailable	3 / 4
2026-08-20	Unavailable	Unavailable	3 / 4
2026-08-21	Unavailable	Unavailable	3 / 4
2026-08-22	Unavailable	Unavailable	3 / 4
2026-08-23	Unavailable	Unavailable	3 / 4
2026-08-24	Unavailable	Unavailable	3 / 4
2026-08-25	Unavailable	Unavailable	3 / 4
2026-08-26	Unavailable	Unavailable	3 / 4
2026-08-27	Unavailable	Unavailable	3 / 4
2026-08-28	Unavailable	Unavailable	3 / 4
2026-08-29	Unavailable	Unavailable	3 / 4
2026-08-30	Unavailable	Unavailable	3 / 4
2026-08-31	Unavailable	Unavailable	3 / 4
2026-09-01	Unavailable	Unavailable	3 / 4
2026-09-02	Unavailable	Unavailable	2 / 3
2026-09-03	Unavailable	Unavailable	2 / 3
2026-09-04	Unavailable	Unavailable	2 / 3
2026-09-05	Unavailable	Unavailable	2 / 3
2026-09-06	Unavailable	Unavailable	2 / 3
2026-09-07	Unavailable	Unavailable	2 / 3
2026-09-08	Unavailable	Unavailable	2 / 3
2026-09-09	Unavailable	Unavailable	2 / 3
2026-09-10	Unavailable	Unavailable	2 / 3
2026-09-11	Unavailable	Unavailable	2 / 3
2026-09-12	Unavailable	Unavailable	2 / 3
2026-09-13	Unavailable	Unavailable	2 / 3
2026-09-14	Unavailable	Unavailable	2 / 3
2026-09-15	Unavailable	Unavailable	2 / 3
2026-09-16	Unavailable	Unavailable	2 / 3
2026-09-17	Unavailable	Unavailable	2 / 3
2026-09-18	Unavailable	Unavailable	2 / 3
2026-09-19	Unavailable	Unavailable	2 / 3
2026-09-20	Unavailable	Unavailable	2 / 3
2026-09-21	Unavailable	Unavailable	2 / 3
2026-09-22	Unavailable	Unavailable	2 / 3
2026-09-23	Unavailable	Unavailable	2 / 3
2026-09-24	Unavailable	Unavailable	2 / 3
2026-09-25	Unavailable	Unavailable	2 / 3
2026-09-26	Unavailable	Unavailable	2 / 3
2026-09-27	Unavailable	Unavailable	2 / 3
2026-09-28	Unavailable	Unavailable	2 / 3
2026-09-29	Unavailable	Unavailable	2 / 3
2026-09-30	Unavailable	Unavailable	2 / 3
2026-10-01	Unavailable	Unavailable	2 / 3
2026-10-02	Unavailable	Unavailable	2 / 3
2026-10-03	Unavailable	Unavailable	2 / 3
2026-10-04	Unavailable	Unavailable	2 / 3
2026-10-05	Unavailable	Unavailable	2 / 3
2026-10-06	Unavailable	Unavailable	2 / 3
2026-10-07	Unavailable	Unavailable	2 / 3
2026-10-08	Unavailable	Unavailable	2 / 3
2026-10-09	Unavailable	Unavailable	2 / 3
2026-10-10	Unavailable	Unavailable	2 / 3
2026-10-11	Unavailable	Unavailable	2 / 3
2026-10-12	Unavailable	Unavailable	2 / 3
2026-10-13	Unavailable	Unavailable	2 / 3
2026-10-14	Unavailable	Unavailable	2 / 3
2026-10-15	Unavailable	Unavailable	2 / 3
2026-10-16	Unavailable	Unavailable	2 / 3
2026-10-17	Unavailable	Unavailable	2 / 3
2026-10-18	Unavailable	Unavailable	2 / 3
2026-10-19	Unavailable	Unavailable	2 / 3
2026-10-20	Unavailable	Unavailable	2 / 3
2026-10-21	Unavailable	Unavailable	2 / 3
2026-10-22	Unavailable	Unavailable	2 / 3
2026-10-23	Unavailable	Unavailable	2 / 3
2026-10-24	Unavailable	Unavailable	2 / 3

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold
2026-05-01	4	1
2026-06-01	4	1
2026-07-01	4	1
2026-08-01	4	1
2026-09-01	4	1
2026-10-01	3	1

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 3 Buy / Strong Buy · 1 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Maintain gross margin between 61-63% in 2026Gross margin: 65.14%
Achieve positive adjusted EBITDA and cash flow in 2026Direct metric needs a verified mapping
Achieve 15-22% revenue growth in 2026Revenue growth: 18.15%

Next proof point

Nov 10, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

1.3%Typical daily move · historical

Downside history

-55.1%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

KORU Medical Systems, Inc. outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

KRMD is a high-risk growth business with a healthcare-sector tailwind, rather than a proven, profitable compounder. Its multi-year view remains intact, but the business is still loss-making and its valuation is expensive versus peers.

What's priced into KORU Medical Systems, Inc.

KRMD trades at a durable premium to peers, and the valuation is tagged as justified with low signs of fragility. The expectations gap is negative, suggesting expectations may be demanding relative to the evidence, despite recent results holding in the top half of its industry.

What the fundamentals likely do

Near term, revenue growth is on track: second-quarter revenue rose 18.2% year over year, within management’s 2026 growth range. Adjusted EBITDA improved and operating cash flow was positive in the first two quarters, while gross margin exceeded management’s stated range in the second quarter. The business remains loss-making and risk has recently been raised to high; a guidance cut or a weaker economy could pressure execution.

What KORU Medical Systems, Inc. hinges on

The multi-year thesis depends on KRMD sustaining growth while turning improving adjusted EBITDA and cash flow into durable profitability. A guidance cut is a clear negative scenario, while continued strength from healthcare bellwethers could support the sector backdrop. Weaker jobs data could raise recession concerns and add pressure to healthcare names.